problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201056135-41problendo-4792Research ArticleСтатьиArticlesЭффективность бивалоса (стронция ранелата) у больных постменопаузальным остеопорозом, не принимающих добавки кальция и витамин DEfficacy and safety of Bivalos therapy in patients with postmenopausal osteoporosis without calcium and vitamin D supplementMarchenkovaL A-Dreval'A V-KriukovaI V-VishniakovaM V-PoliakovaE Iu-TisheninaR S-RubinM P-201015022010561ТОМ 56, №1 (2010)3541Copyright © Marchenkova L.A., Dreval' A.V., Kriukova I.V., Vishniakova M.V., Poliakova E.I., Tishenina R.S., Rubin M.P., 20102010Marchenkova L.A., Dreval' A.V., Kriukova I.V., Vishniakova M.V., Poliakova E.I., Tishenina R.S., Rubin M.P.Marchenkova L.A., Dreval' A.V., Kriukova I.V., Vishniakova M.V., Poliakova E.I., Tishenina R.S., Rubin M.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4792постменопаузальный остеопорозвитамин Dтерапияpostmenopausal osteoporosisvitamin DtherapyReferencesBell N.H., Bilezikian J.P. et al. Alendronate increases bone mass and reduces markers in postmenopausal African-American women J Clin Endocrinol Metabol 2002; 87: 6: 2792-2797.Bell N.H., Bilezikian J.P. et al. Alendronate increases bone mass and reduces markers in postmenopausal African-American women J Clin Endocrinol Metabol 2002; 87: 6: 2792-2797.Black D.M., Delmas P.D., Estell R. et al. Once-early zoledronic acid for treatment of postmenopausal octeoporosis. N Engl J Med 2007; 356: 1809-1822.Black D.M., Delmas P.D., Estell R. et al. Once-early zoledronic acid for treatment of postmenopausal octeoporosis. N Engl J Med 2007; 356: 1809-1822.Neer R.M., Arnaud C.D., Zanchetta J.R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Engl J Med 2001; 35: 1434-1441.Neer R.M., Arnaud C.D., Zanchetta J.R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Engl J Med 2001; 35: 1434-1441.Caverzasio J. et al. Strontium ranelate increases osteoblast replication through activation of an original cellular mechanism. Calcified Tissue Int 2007; 80 (suppl 1): S74.Caverzasio J. et al. Strontium ranelate increases osteoblast replication through activation of an original cellular mechanism. Calcified Tissue Int 2007; 80 (suppl 1): S74.Canalis E., Hott M. et al. The divalent strontium solt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996: 18: 517-523.Canalis E., Hott M. et al. The divalent strontium solt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996: 18: 517-523.Atkins G.J., Welldon K.J., Findlay D.M. et al. Strontium ranelate promotes an osteocyte-like phenotype from human primary osteoblasts ex vivo. Calcified Tissue Int 2007; 80 (suppl 1): 71-72.Atkins G.J., Welldon K.J., Findlay D.M. et al. Strontium ranelate promotes an osteocyte-like phenotype from human primary osteoblasts ex vivo. Calcified Tissue Int 2007; 80 (suppl 1): 71-72.Рожинская Л.Я., Беляева А.В., Белая Ж.Е. Ранелат стронция (Бивалос) - препарат двойного действия на костную ткань; новые подходы к лечению остеопороза. Остеопороз и остеопатии 2006; 1: 32-37.Рожинская Л.Я., Беляева А.В., Белая Ж.Е. Ранелат стронция (Бивалос) - препарат двойного действия на костную ткань; новые подходы к лечению остеопороза. Остеопороз и остеопатии 2006; 1: 32-37.Остеопороз: диагностика, профилактика и лечение (клинические рекомендации). Под ред. О.М. Лесняк, Л.И. Беневоленской 2-е изд. М: ГЭОТАР-Медиа 2009; 272.Остеопороз: диагностика, профилактика и лечение (клинические рекомендации). Под ред. О.М. Лесняк, Л.И. Беневоленской 2-е изд. М: ГЭОТАР-Медиа 2009; 272.Marquis P., Roux C., de la Loge C. et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteopor Int 2008; 19: 4: 503-510.Marquis P., Roux C., de la Loge C. et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteopor Int 2008; 19: 4: 503-510.Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Eng J Med 2004; 350: 459-468.Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Eng J Med 2004; 350: 459-468.Reginster J..Y, Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 5: 2816-2822.Reginster J..Y, Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 5: 2816-2822.Rizzoli R., Boonen S., Brandi M.L. et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246-249.Rizzoli R., Boonen S., Brandi M.L. et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246-249.Lips P., Cooper C., Agnusdei D. et al. Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Osteopor Int 1999; 10: 150-160. doi: 10.1007 s001980050210.Lips P., Cooper C., Agnusdei D. et al. Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Osteopor Int 1999; 10: 150-160. doi: 10.1007 s001980050210.Lips P., Cooper C. Qualeffo-41 scoring algorithm (updated 31.10.2005). Available from: http://www.iofbonehealth.org.Lips P., Cooper C. Qualeffo-41 scoring algorithm (updated 31.10.2005). Available from: http://www.iofbonehealth.org.Bruyère O., Roux C., Detilleux J. et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 8: 3076-3081.Bruyère O., Roux C., Detilleux J. et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 8: 3076-3081.Рожинская Л.Я., Арапова С.Д., Дзеранова Л.К. и др. Результаты российского многоцентрового исследования эффективности и переносимости Бивалоса (стронция ранелата) у женщин с постменопаузальным остеопорозом. Остеопороз и остеопатии 2007; 3: 24-30.Рожинская Л.Я., Арапова С.Д., Дзеранова Л.К. и др. Результаты российского многоцентрового исследования эффективности и переносимости Бивалоса (стронция ранелата) у женщин с постменопаузальным остеопорозом. Остеопороз и остеопатии 2007; 3: 24-30.Древаль А.В., Марченкова Л.А., Крюкова И.В. и др. Эффективность, переносимость и комплаентность алендроната натрия (70 мг 1 раз в неделю) при лечении постменопаузального остеопороза. Остеопороз и остеопатии 2006; 2: 13-17.Древаль А.В., Марченкова Л.А., Крюкова И.В. и др. Эффективность, переносимость и комплаентность алендроната натрия (70 мг 1 раз в неделю) при лечении постменопаузального остеопороза. Остеопороз и остеопатии 2006; 2: 13-17.Rizzoli R., Greenspan S.L. at al. Two-years results of onсe-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis J Bone Min Res 2002; 17: 1988-1996.Rizzoli R., Greenspan S.L. at al. Two-years results of onсe-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis J Bone Min Res 2002; 17: 1988-1996.Massari F., Zanchetta S.R. et al. PTH levels in posmenopausal women with osteoporosis treated with alendronate. J Bone Min Res 1997; 12 (Suppl 1): 4Massari F., Zanchetta S.R. et al. PTH levels in posmenopausal women with osteoporosis treated with alendronate. J Bone Min Res 1997; 12 (Suppl 1): 4
The authors declare that there are no conflicts of interest present.